-
Innovation Ranking
Innovation Ranking – Infinity Pharmaceuticals Inc
Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company which discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. The company is evaluating IPI-549 as a monotherapy and in a combination therapy in various clinical trials for the treatment of various indications such advanced solid tumors, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple...
-
Sector Analysis
NewNCAA Basketball Championships 2024 – Event Analysis
NCAA Basketball Championships 2024 Event Analysis Report Overview The estimated annual sponsorship value of the 2024 NCAA Basketball Championship was $277 million. March Madness is the annual men’s and women’s basketball championship of the National Collegiate Athletic Association (NCAA) Division 1, attracting great interest from fans and media across the United States. The 2024 NCAA Basketball Championships had in place a sponsorship portfolio of 21 brands. Both the men’s and women’s tournaments offer brands major advertising opportunities while millions of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Solid Tumor Drug Details: Eganelisib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Hypopharyngeal Cancer Drug Details: Eganelisib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Laryngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Laryngeal Cancer Drug Details: Eganelisib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Nasopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Nasopharyngeal Cancer Drug Details: Eganelisib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Human Papillomavirus (HPV) Associated Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Human Papillomavirus (HPV) Associated Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Human Papillomavirus (HPV) Associated Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Oral Cavity (Mouth) Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Oral Cavity (Mouth) Cancer Drug Details: Eganelisib...